Labcorp Holdings Inc. (LH)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE
Market Cap: $30.08B
Last updated: Nov 17, 2026 at 4:15 PM ET
Labcorp Holdings Inc. (LH) Statistics
Labcorp Holdings (LH) has a market cap of $30.08B and an enterprise value of $35.67B. Its trailing P/E of 20.4x is above its 10-year median of 15.3x. Its share count is down 2.05% from a year earlier.
Total Valuation
Enterprise value is 18.58% above the market cap, as debt exceeds cash.
| Market Cap | $30.08B |
|---|---|
| Enterprise Value | $35.67B |
| Latest price (Nov 17, 2026) | $368.27 |
Key Dates
The next earnings report is expected on Feb 15, 2027, covering the quarter ending Dec 31, 2026. The next ex-dividend date is Nov 24, 2026.
| Next Earnings Date | Feb 15, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 28, 2026 |
| Next Ex-Dividend Date | Nov 24, 2026 |
| Next Payment Date | Dec 11, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 2.0x and 3.4x. Its year-end P/E ranged from 8.5x to 16.6x from 2016 to 2025.
| P/E Ratio | 20.4x |
|---|---|
| Forward P/E | 19.3x |
| P/S Ratio | 2.0x |
| Forward P/S | 2.0x |
| P/B Ratio | 3.4x |
| P/FCF Ratio | 23.2x |
| P/OCF Ratio | 16.6x |
| PEG Ratio | 3.3 |
Enterprise Valuation
Counting debt and cash, the company is valued at 17.6x EBITDA and 27.6x free cash flow.
| EV / Earnings | 35.5x |
|---|---|
| EV / Sales | 2.4x |
| EV / EBITDA | 17.6x |
| EV / EBIT | 24.4x |
| EV / FCF | 27.6x |
Price Statistics
The stock is up 38.70% over 52 weeks and trades 11.12% above its 50-day average.
| Beta (1Y) | 0.34 |
|---|---|
| 52-Week Change | +38.70% |
| 1-Month Change | +15.51% |
| 3-Month Change | +11.69% |
| 6-Month Change | +45.88% |
| 5-Year Change | +25.91% |
| 10-Year Change | +188.33% |
| Total Return (1Y) | +39.79% |
| Total Return (3Y CAGR) | +21.12% |
| Total Return (5Y CAGR) | +9.27% |
| Return vs SPY (1Y) | +30.92% |
| Max Drawdown (1Y) | -13.59% |
| Max Drawdown (3Y) | -17.36% |
| Sharpe Ratio (1Y) | 1.49 |
| Correlation with SPY (1Y) | 0.20 |
| 50-Day Average | $331.42 |
| 200-Day Average | $292.75 |
| 52-Week Range | $243.20 to $375.10 |
| RSI (14 Days) | 65.4 |
| Average Volume (20 Days) | 780.92K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.41x current liabilities, and total debt is 0.66x shareholder equity.
| Current Ratio | 1.41x |
|---|---|
| Quick Ratio | 1.22x |
| Debt / Equity | 0.66x |
| Debt / EBITDA | 2.90x |
| Debt / FCF | 4.55x |
| Interest Coverage | 6.34x |
Returns and Efficiency
Return on invested capital is 8.16% over the last 12 months, against a 5-year average of 7.93%.
| Return on Equity (ROE) | 11.36% |
|---|---|
| Return on Assets (ROA) | 5.31% |
| Return on Invested Capital (ROIC) | 8.16% |
| Return on Capital Employed (ROCE) | 9.07% |
| ROE (5Y Average) | 12.13% |
| ROA (5Y Average) | 5.87% |
| ROIC (5Y Average) | 7.93% |
| Asset Turnover | 0.78x |
| Inventory Turnover | 18.84x |
| Receivables Turnover | 5.76x |
| Cash Conversion Cycle | 58 days |
Taxes
Income tax took 17.93% of pretax income over the last 12 months.
| Income Tax (TTM) | $219.60M |
|---|---|
| Effective Tax Rate | 17.93% |
Scores
LH has an Altman Z-Score of 3.54, in the safe zone above 2.99, and a Piotroski F-Score of 8 of 9, in the strong band of 8 or 9.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 3.54 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 8 of 9 |
| Piotroski Strength | Strong |
Income Statement
Revenue of $14.59B over the last 12 months is up 6.02% from the 12 months before.
| Revenue | $14.59B |
|---|---|
| Revenue Growth (YoY) | +6.02% |
| Gross Profit | $4.23B |
| Operating Income | $1.50B |
| Pretax Income | $1.22B |
| Net Income | $1.01B |
| EBITDA | $2.02B |
| EBIT | $1.46B |
| Reported EPS (TTM) | $18.09 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 46.78% of the $18.92B in total assets.
| Cash and Equivalents | $261.80M |
|---|---|
| Total Debt | $5.85B |
| Net Debt | $5.59B |
| Net Debt Per Share | $68.84 |
| Working Capital | $1.15B |
| Shareholder Equity | $8.85B |
| Book Value Per Share | $108.96 |
| Tangible Book Value | -$2.05B |
| Total Assets | $18.92B |
| Total Liabilities | $10.06B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $528.10M of capital spending, operating cash flow left $1.29B of free cash flow.
| Operating Cash Flow | $1.81B |
|---|---|
| Capital Expenditures | $528.10M |
| Free Cash Flow | $1.29B |
| FCF Per Share | $15.85 |
| Depreciation and Amortization | $559.20M |
| Dividends Paid | $237.40M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 10.29%, against a 5-year average of 11.91%.
| Gross Margin | 28.96% |
|---|---|
| Operating Margin | 10.29% |
| Pretax Margin | 8.39% |
| Net Margin | 6.89% |
| EBITDA Margin | 13.84% |
| EBIT Margin | 10.01% |
| FCF Margin | 8.82% |
| Gross Margin (5Y Average) | 30.71% |
| Operating Margin (5Y Average) | 11.91% |
| Net Margin (5Y Average) | 8.88% |
Growth
Revenue grew 5.55% a year over 3 years, and EPS fell 6.15% a year.
| Revenue Growth (3Y CAGR) | +5.55% |
|---|---|
| Revenue Growth (5Y CAGR) | -0.04% |
| EPS Growth (3Y CAGR) | -6.15% |
| EPS Growth (5Y CAGR) | -7.22% |
| FCF Growth (3Y CAGR) | -7.56% |
| FCF Growth (5Y CAGR) | -7.21% |
| Operating Income Growth (3Y CAGR) | -1.22% |
| Book Value Per Share Growth (2Y CAGR) | +5.69% |
Dividends and Yields
LH pays out 12.88% of earnings as dividends.
| Dividend Per Share (Annual) | $2.88 |
|---|---|
| Dividend Yield | 0.78% |
| Payment Schedule | Quarterly |
| Payout Ratio | 12.88% |
| FCF Payout Ratio | 18.45% |
| Earnings Yield | 4.90% |
| FCF Yield | 4.30% |
| Buyback Yield | 1.98% |
| Shareholder Yield | 2.78% |
Stock Splits
The last split was a 2-for-1 forward split on May 13, 2002.
| Last Split Date | May 13, 2002 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 2:1 |
Peer Position
Against 11 similar companies, LH has the lowest P/E and the 7th highest ROIC.
P/E RatioPeer median 31.3x
P/S RatioPeer median 6.5x
ROICPeer median 8.47%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +8.73%
Dividend YieldPeer median 0.00%
| P/E Ratio | 20.4x vs 31.3x median |
|---|---|
| P/S Ratio | 2.0x vs 6.5x median |
| ROIC | 8.16% vs 8.47% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +6.02% vs +8.73% median |
| Dividend Yield | 0.78% vs 0.00% median |
Analyst Forecast
Consensus estimates put revenue growth at 5.83% and EPS growth at 9.19% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +5.83% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +9.19% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About LH
What is LH's market cap?
Labcorp Holdings has a market cap of $30.08B. Its enterprise value, which adds debt and subtracts cash, is $35.67B.
What is LH's P/E ratio?
Labcorp Holdings has a trailing P/E ratio of 20.4x and a forward P/E of 19.3x.
How many shares of LH are outstanding?
Labcorp Holdings has 81.20M shares outstanding. The count is down 2.05% from a year earlier.
Does LH pay a dividend?
Yes. Labcorp Holdings pays $2.88 a share a year, a dividend yield of 0.78%.
How much debt does LH have?
Labcorp Holdings has $5.85B of total debt and $261.80M of cash and equivalents, a net debt position of $5.59B.
LH pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts